Oculis Holding AG Earnings Call Transcripts
Fiscal Year 2026
-
Three late-stage assets are advancing in large ophthalmic and neuro-ophthalmic markets, with OCS-01 phase III results expected in June, licaminlimab targeting a genotype-defined dry eye population, and privosegtor in registrational trials for rare optic neuropathies. Strong financials and regulatory support position the pipeline for multiple milestones through 2027.
-
Three phase III programs are advancing, with a topical DME therapy nearing pivotal data and a biomarker-driven dry eye trial set for Q4 results. Neuroprotection candidate Privosegtor shows strong efficacy in optic neuritis, with premium pricing anticipated.
-
Three late-stage assets are advancing: OCS-01 for DME expects phase III results in Q2 and targets 2027 approval; Licaminlimab targets dry eye with a precision approach and 2026 readout; Privosegtor leads in neuroprotection with phase III trials and breakthrough status. Rapid adoption and large market opportunities are expected, backed by strong execution and financial stability.
Fiscal Year 2025
-
The company is advancing late-stage programs in neuro-ophthalmology and ophthalmology, with Privosegtor showing strong efficacy in acute optic neuritis and moving into pivotal trials for AON and NAION. OCS-01 and OCS-02 target DME and dry eye, with innovative approaches and significant market potential.
-
Three late-stage assets are advancing, led by OCS-05 for acute optic neuritis, which showed strong neuroprotection and is entering two phase III trials. Licaminlimab targets dry eye disease with a precision medicine approach, and OCS-01 is in phase III for DME. Cash runway extends to 2029.
-
Privosegtor advances to registration trials for AON and NAION after FDA alignment, with PIONEER-1 starting in Q4 2025 and PIONEER-3 for NAION in mid-2026. Both indications represent multi-billion dollar opportunities, and trial designs mirror the successful ACUITY phase II study.
-
Three clinical-stage assets are advancing, with OCS-01 in phase 3 for DME showing strong efficacy and safety, OCS-05 demonstrating neuroprotection in acute optic neuritis, and OCS-02 targeting dry eye with a biomarker-driven approach. Cash runway extends to 2028, supporting key milestones.
-
Three late-stage clinical programs are prioritized based on market potential and likelihood of success, with OCS-01 for DME leading and phase 3 readout expected in Q2 2026. OCS-05 advances in AON and MS relapse, while OCS-02 uses a genotype-based approach for dry eye. Cash runway extends to early 2028.
-
Panelists discussed pivotal-stage therapies for retinal disorders, highlighting advances in gene therapy, mitochondrial-targeted drugs, and non-invasive delivery methods. Key challenges include compliance, reimbursement, and trial execution, with several Phase 3 readouts and regulatory milestones expected in the next two years.
-
Three innovative ophthalmology and neuro-ophthalmology assets are advancing through late-stage trials, targeting large unmet needs in DME, AON, and dry eye disease. Robust clinical data, regulatory alignment, and a strong financial position support multiple upcoming catalysts.
-
A diversified ophthalmology pipeline is advancing with three core assets targeting DME, dry eye, and neuro-ophthalmology diseases. Privosegtor showed strong phase 2 results in acute optic neuritis and is expanding into NAION and MS relapses. Key regulatory milestones and trial readouts are expected over the next two years.
-
Oculis presented a robust pipeline targeting major unmet needs in ophthalmology and neuro-ophthalmology, with late-stage clinical progress for DME, acute optic neuritis, and dry eye disease. Key assets are advancing toward pivotal trials and regulatory milestones in 2024–2026.
-
Three first-in-class assets are advancing in late-stage trials for DME, acute optic neuritis, and dry eye, each targeting large unmet needs. OCS-01 and OCS-02 leverage innovative delivery and precision medicine, while Privosegtor expands into neuroprotection. Multiple catalysts are expected in 2025.
-
Three lead assets are prioritized: OCS-01 for DME, Licaminlimab for dry eye, and Privosegtor for neuroprotection, each showing strong clinical progress and market potential. Precision medicine and neuroprotection breakthroughs are highlighted, with pivotal trials and regulatory milestones ahead.
-
Three innovative ophthalmology assets advanced significantly, with OCS-05 showing strong neuroprotection in AON, OCS-02 demonstrating precision efficacy in dry eye, and OCS-01 delivering promising DME results. Cash runway exceeds $200M, supporting milestones into 2028.
-
Phase II results for OCS-05 in acute optic neuritis showed strong safety and significant neuroprotective efficacy, preserving retinal structure and improving vision. Experts highlighted the unprecedented translation of preclinical to clinical benefit, supporting further development in optic neuritis and other neurodegenerative diseases.
Fiscal Year 2024
-
Three late-stage ophthalmology assets are advancing, with OCS-01 showing strong phase III efficacy in DME and post-surgical inflammation, OCS-02 targeting dry eye with a precision medicine approach, and OCS-05 poised for neuroprotection data. Cash runway extends into 2026.
-
Three clinical-stage assets target major unmet needs in ophthalmology, with OCS-01 advancing in DME and ocular surgery, OCS-02 leveraging a biomarker-driven approach in dry eye, and OCS-05 nearing key data in optic neuritis. All programs are fully funded through 2026.
-
The conference featured updates on a robust ophthalmology pipeline, including phase III progress for DME and dry eye, precision medicine advances with a TNFR1 biomarker, and a strong financial position. Key trial readouts and regulatory milestones are expected in late 2024 and early 2025.
-
Major advances in ophthalmic drug development were presented, including a topical eye drop for diabetic macular edema with efficacy matching injections, and a neuroprotective agent in late-stage trials. Strong financials support continued innovation and multiple near-term milestones.
-
RELIEF phase II-B trial of licaminlimab in dry eye disease showed rapid, significant improvement in signs, especially in TNFR1 genotype-positive patients, with a strong safety profile and potential for precision medicine. The results support advancing to phase III with a targeted, efficient approach.